Nanoscope Therapeutics
Nanoscope Therapeutics Inc. is a clinical-stage biotechnology company that is developing gene-agnostic therapies for individuals with retinal degenerative diseases. In October 2022, the company announced the FDA has granted Fast Track Designation to their asset MCO-010, an optogenetic monotherapy, that through injection can be a treatment for retinitis pigmentosa (RP). Having a Fast Track Designation is significant because it expedites the review process of a novel therapy by allowing for increased communication with the FDA regarding regulatory hurdles.
In March 2023, Nanoscope announced positive topline results from its Phase 2b RESTORE Trial of MCO-010 for the treatment of retinitis pigmentosa.
In October 2024, Nanoscope presented conclusive trial data that demonstrated high and low doses of MCO-010 led to a statistically significant improvement in visual acuity over patients who received a placebo. The degree and duration of visual improvement achieved in the trial were unprecedented. Following these promising results, Nanoscope plans to file a Biologics License Application (BLA) in early 2025 to seek approval for marketing and commercializing this groundbreaking treatment.
Nanoscope Therapeutics website
Clinicaltrials.gov ID NCT04945772
Nanoscope Related Science News
Nanoscope Therapeutics announced positive top-line results from a Phase 2b trial of MCO-010 for retinitis pigmentosa (RP).
Nanoscope Therapeutics Inc., a clinical-stage biotechnology company, has recently announced that one of its drugs is approved for Phase 2b clinical trial.
